Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Triferic PK Equivalence in Hemodialysis
NCT03303144Phase 2Completed
- Sponsor
- Rockwell Medical
- Start
- Oct 2017
- Primary completion
- Dec 2017
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of ferric pyrophosphate in end stage renal disease (ESRD) (3 arms), sponsored by Rockwell Medical. Primary endpoints: Pharmacokinetics (PK) of Triferic Iron Administered Via Hemodialysate: Cmax at 12 hours, Pharmacokinetics (PK) of Triferic Iron Administered IV: Cmax at 12 hours and 1 more. Started Oct 2017; status: completed.
02
Drugs
ferric pyrophosphate
03
Conditions
end stage renal disease (ESRD)
Beyond the preview
Go deeper on NCT03303144.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03303144.